Director receives 59,667 Serina Therapeutics shares

Serina Therapeutics director Bailey Gregory acquired additional common stock through a share award.

Rhea-AI Filing Summary

Serina Therapeutics director Bailey Gregory acquired additional common stock through a share award. On March 31, 2026, Gregory received 59,667 shares of Serina Therapeutics common stock at $1.94 per share in a grant classified as a “grant, award, or other acquisition.”

According to a footnote, these shares were issued as payment of accrued dividends on the reporting individual’s Series A Convertible Preferred Stock issued on April 8, 2025. Following this transaction, Gregory directly holds 126,910 shares of Serina Therapeutics common stock.

Insider Trade Summary

Grant/Award: 59,667 shares

Grant/Award 1 txn

Insider Bailey Gregory

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	59,667	$1.94	$116K

Holdings After Transaction: Common Stock — 126,910 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were issued for payment of accrued dividends on the reporting individuals Series A Convertible Preferred Stock issued on April 8, 2025.

Key Figures

Shares acquired: 59,667 shares Transaction price per share: $1.94 per share Total shares after transaction: 126,910 shares

3 metrics

Shares acquired 59,667 shares Grant on March 31, 2026

Transaction price per share $1.94 per share Value assigned to granted common stock

Total shares after transaction 126,910 shares Director’s direct holdings following grant

Key Terms

Grant, award, or other acquisition, Series A Convertible Preferred Stock, accrued dividends

3 terms

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Series A Convertible Preferred Stock financial

"accrued dividends on the reporting individuals Series A Convertible Preferred Stock"

Series A convertible preferred stock is a class of shares sold in an early funding round that gives investors a mix of protection and upside: it pays a priority claim over common shares if the company is sold or closes, but can be converted into ordinary shares to share in future growth. Think of it like a hybrid between a safer stake and a ticket to ownership; it matters to investors because it affects who controls the company, how future gains are split, and how much their investment is protected from downside.

accrued dividends financial

"were issued for payment of accrued dividends on the reporting individuals Series A"

Accrued dividends are payments a company owes to shareholders that have been earned or officially declared but not yet paid; think of them as an IOU the company has for past dividend obligations. They matter to investors because they represent a near-term claim on a company’s cash, affect the company’s reported liabilities and value, and can be especially important when assessing income reliability or priority in a payout situation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Serina Therapeutics (SER) disclose for Bailey Gregory?

Serina Therapeutics reported that director Bailey Gregory acquired 59,667 shares of common stock. The shares were received as a grant labeled “grant, award, or other acquisition,” increasing Gregory’s direct holdings to 126,910 shares of Serina Therapeutics common stock.

At what price were the new Serina Therapeutics (SER) shares attributed to Bailey Gregory?

The 59,667 Serina Therapeutics common shares attributed to Bailey Gregory were valued at $1.94 per share. This price is the transaction price per share disclosed for the grant, which reflects how the share award was recorded in the insider reporting data.

Why did Bailey Gregory receive additional Serina Therapeutics (SER) common stock?

The filing states that the shares were issued as payment of accrued dividends on the reporting individual’s Series A Convertible Preferred Stock. That preferred stock was issued on April 8, 2025, and the accrued dividends were settled using newly issued common shares.

How many Serina Therapeutics (SER) shares does Bailey Gregory hold after this transaction?

After receiving 59,667 additional common shares, Bailey Gregory directly holds a total of 126,910 Serina Therapeutics shares. This total reflects Gregory’s position immediately following the reported grant transaction, as disclosed in the insider filing data.

Is Bailey Gregory’s Serina Therapeutics (SER) transaction an open-market buy or a grant?

The transaction is reported with code A, described as a “grant, award, or other acquisition,” not an open-market purchase. The shares were issued to pay accrued dividends on Series A Convertible Preferred Stock rather than being bought on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 03:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bailey Gregory

(Last) (First) (Middle)

601 GENOME WAY, SUITE 2001

(Street)

HUNTSVILLE ALABAMA 35806

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Serina Therapeutics, Inc. [ SER ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		A		59,667(1)	A	$1.94	126,910	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were issued for payment of accrued dividends on the reporting individuals Series A Convertible Preferred Stock issued on April 8, 2025.

Remarks:

	/s/ Gregory Bailey	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)